Hot Topics in Bladder and Prostate Cancer: Latest Treatments and Case-Based Learning

Date
Friday, December 6, 2024
 
Time
8:00 AM (UTC-04:00) Eastern Time (US & Canada)
 
Duration
60 minutes
 
Credit Type
CME/CPE/CNE/AANP/AAPA
 
Intended Learners

This educational activity is specifically designed for clinicians who specialize in urologic oncology involved and/or interested in the therapeutic management of patients with urologic malignancies and conditions.

 
Learning Objectives

After participating in this activity, learners should be better able to:

  • Describe diagnostic and prognostic biomarkers and emerging applications for next generation imaging in staging and treatment selection for MIBC, HER-2+ mUC and de novo mHSPC
  • Evaluate recent clinical trial data and its implications for treatment selection and sequencing in MIBC, HER-2+ mUC and de novo mHSPC
  • Evaluate the evolving landscape of neoadjuvant treatment in MIBC and de novo mHSPC treatment and the implications for patient care
  • Implement the most current guideline recommendations and patient-centered care strategies to improve MIBC, mUC and de novo mHSPC diagnosis, treatment, and outcomes
 
Continuing Education
 
Jointly Accredited Provider
 

In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Note: This statement is not an indication of approved credits. Check back soon for full accreditation information.

This activity is supported by an independent educational grant from AstraZeneca.

 

Speakers

Jason A. Efstathiou, MD, DPHIL, FASTRO, FACRO
Jason A. Efstathiou, MD, DPHIL, FASTRO, FACRO
Massachusetts General Hospital/Mass General Brigham
Co-Director, Bertucci Center for GU Cancers
Daniel P. Petrylak, MD
Daniel P. Petrylak, MD
Yale School of Medicine
Professor of Medicine (Medical Oncology) and of Urology
Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS
Carolina Urologic Research Center
Medical Director

This symposium is not part of the official Annual Meeting of the Society of Urologic Oncology educational program as planned by SUO’s Educational Meetings Committee.